Development and clinical applications of an enclosed automated targeted NGS library preparation system
•The first fully enclosed cassette-dependent automated library preparation system for NGS.•Simply to use – reducing manual operation time and complexity.•Fully enclosed environment – highly resistance to cross-contamination.•Verified in clinical practice that can be use for detection of both germ li...
Gespeichert in:
Veröffentlicht in: | Clinica chimica acta 2023-02, Vol.540, p.117224-117224, Article 117224 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •The first fully enclosed cassette-dependent automated library preparation system for NGS.•Simply to use – reducing manual operation time and complexity.•Fully enclosed environment – highly resistance to cross-contamination.•Verified in clinical practice that can be use for detection of both germ line or somatic mutations.
The rapid development of next-generation sequencing (NGS) technology has promoted its wide clinical application in precision medicine for oncology. However, laborious and time-consuming manual operations, highly skilled personnel requirements, and cross-contamination are major challenges for the clinical implementation of NGS technology-based tests. The Automated NGS Diagnostic Solutions (ANDiS) 500 system is a fully enclosed cassette-dependent automated NGS library preparation system. This platform could produce qualified targeted amplicon library in three steps with only 15 min of hands-on time. Rigorous cross-contamination test using simulated contaminant plasmids confirmed that the design of disposable cassette guarantees zero sample cross-contamination. The BRCA1 and BRCA2 mutation detection panel and gastrointestinal cancer-related gene analysis panel for the ANDiS 500 platform showed 100% accuracy and precision in detecting germ-line mutations and somatic mutations respectively. Furthermore, those panels showed 100% concordance with verified methods in a prospective cohort study enrolling 363 patients and a cohort of 45 pan-cancer samples. In conclusion, the ANDiS 500 automated platform could overcome major challenges for implementing NGS assays clinically and is eligible for routine clinical tests. |
---|---|
ISSN: | 0009-8981 1873-3492 |
DOI: | 10.1016/j.cca.2023.117224 |